Brad R Rocco1, David A Lewis2, Kenneth N Fish3. 1. Departments of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. Departments of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Neuroscience, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Departments of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: fishkn@upmc.edu.
Abstract
BACKGROUND: Convergent findings indicate that cortical gamma-aminobutyric acid (GABA)ergic circuitry is altered in schizophrenia. Postmortem studies have consistently found lower levels of glutamic acid decarboxylase 67 (GAD67) messenger RNA (mRNA) in the prefrontal cortex (PFC) of subjects with schizophrenia. At the cellular level, the density of GABA neurons with detectable levels of GAD67 mRNA is ~30% lower across cortical layers. Knowing how this transcript deficit translates to GAD67 protein levels in axonal boutons is important for understanding the impact it might have on GABA synthesis. In addition, because reductions in GAD67 expression before, but not after, the maturation of GABAergic boutons results in a lower density of GABAergic boutons in mouse cortical cultures, knowing if GABAergic bouton density is altered in schizophrenia would provide insight into the timing of the GAD67 deficit. METHODS: PFC tissue sections from 20 matched pairs of schizophrenia and comparison subjects were immunolabeled for the vesicular GABA transporter (vGAT) and GAD67. RESULTS: vGAT+ bouton density did not differ between subject groups, consistent with findings that vGAT mRNA levels are unaltered in the illness and confirming that the number of cortical GABAergic boutons is not lower in schizophrenia. In contrast, in schizophrenia subjects, the proportion of vGAT+ boutons with detectable GAD67 levels (vGAT+/GAD67+ boutons) was 16% lower and mean GAD67 levels were 14% lower in the remaining vGAT+/GAD67+ boutons. CONCLUSIONS: Our findings suggest that GABA production is markedly reduced in a subset of boutons in the PFC of schizophrenia subjects and that this reduction likely occurs after the maturation of GABAergic boutons.
BACKGROUND: Convergent findings indicate that cortical gamma-aminobutyric acid (GABA)ergic circuitry is altered in schizophrenia. Postmortem studies have consistently found lower levels of glutamic acid decarboxylase 67 (GAD67) messenger RNA (mRNA) in the prefrontal cortex (PFC) of subjects with schizophrenia. At the cellular level, the density of GABA neurons with detectable levels of GAD67 mRNA is ~30% lower across cortical layers. Knowing how this transcript deficit translates to GAD67 protein levels in axonal boutons is important for understanding the impact it might have on GABA synthesis. In addition, because reductions in GAD67 expression before, but not after, the maturation of GABAergic boutons results in a lower density of GABAergic boutons in mouse cortical cultures, knowing if GABAergic bouton density is altered in schizophrenia would provide insight into the timing of the GAD67 deficit. METHODS: PFC tissue sections from 20 matched pairs of schizophrenia and comparison subjects were immunolabeled for the vesicular GABA transporter (vGAT) and GAD67. RESULTS:vGAT+ bouton density did not differ between subject groups, consistent with findings that vGAT mRNA levels are unaltered in the illness and confirming that the number of cortical GABAergic boutons is not lower in schizophrenia. In contrast, in schizophrenia subjects, the proportion of vGAT+ boutons with detectable GAD67 levels (vGAT+/GAD67+ boutons) was 16% lower and mean GAD67 levels were 14% lower in the remaining vGAT+/GAD67+ boutons. CONCLUSIONS: Our findings suggest that GABA production is markedly reduced in a subset of boutons in the PFC of schizophrenia subjects and that this reduction likely occurs after the maturation of GABAergic boutons.
Authors: Thomas M Hyde; Barbara K Lipska; Towhid Ali; Shiny V Mathew; Amanda J Law; Ochuko E Metitiri; Richard E Straub; Tianzhang Ye; Carlo Colantuoni; Mary M Herman; Llewellyn B Bigelow; Daniel R Weinberger; Joel E Kleinman Journal: J Neurosci Date: 2011-07-27 Impact factor: 6.167
Authors: T Hashimoto; D Arion; T Unger; J G Maldonado-Avilés; H M Morris; D W Volk; K Mirnics; D A Lewis Journal: Mol Psychiatry Date: 2007-05-01 Impact factor: 15.992
Authors: Takanori Hashimoto; H Holly Bazmi; Karoly Mirnics; Qiang Wu; Allan R Sampson; David A Lewis Journal: Am J Psychiatry Date: 2008-02-15 Impact factor: 18.112
Authors: Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Xiangling Mao; Pablo León-Ortiz; Oscar Rodríguez-Mayoral; Helgi Jung-Cook; Rodolfo Solís-Vivanco; Ariel Graff-Guerrero; Dikoma C Shungu Journal: Biol Psychiatry Date: 2017-10-10 Impact factor: 13.382
Authors: John F Enwright; Sowmya Sanapala; Aaron Foglio; Raissa Berry; Kenneth N Fish; David A Lewis Journal: Neuropsychopharmacology Date: 2016-02-12 Impact factor: 7.853
Authors: Ahmad Alhourani; Kenneth N Fish; Thomas A Wozny; Vivek Sudhakar; Ronald L Hamilton; R Mark Richardson Journal: J Neurophysiol Date: 2019-12-04 Impact factor: 2.714